

**REMARKS**


The present preliminary amendment is being provided in order to correct a typographical error in the citation of a reference. A marked up version of this amended matter is attached.

No new matter has been introduced into the application or substitute specification by this amendment. It is respectfully requested that examination be carried out based on the substitute specification.

Prompt examination of the present application is respectfully requested.

Respectfully submitted,

Qi et al.

By   
C. Frederick Koenig III  
Registration No. 29,662  
(215) 568-6400

Volpe and Koenig, P.C.  
Suite 400, One Penn Center  
1617 John F. Kennedy Boulevard  
Philadelphia, PA 19103

CFK/PDM/fap  
Attachment

Application No.: 10/031,520  
Examiner: Not Yet Known



COPY OF PAPERS  
ORIGINALLY FILED

**RECEIVED**

JUL 25 2002

**TECH CENTER 1600/2900**

**37 CFR §1.121(b)(1)(iii) and (c)(1)(ii) SPECIFICATION  
AMENDMENTS- MARKED UP VERSION**

**In the Specification:**

The paragraph spanning lines 17 through 23 on page 1 should read:

-- Japanese patent application 58-128322 discloses a proteoglycan extracted from microalgae and spirulina inhibiting the growth of leukemia cells. However, no other activities of such a proteoglycan have been disclosed in this application. Although a process for extraction of the proteoglycan from spirulina disclosed therein, the process fails to involve the step of breaking the cellular wall of spirulina. Therefore, the process in this Japanese patent application is expected to be only applied in the laboratory, rather than in the industry with a large scale. --